On The Pen GLP-1 News
Claim This Podcastby Dave Knapp GLP-1 Industry Insider
Podcast Overview
<p>On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.</p><p><br /></p>
Language
🇺🇲
Publishing Since
1/14/2024
Reach the team behind On The Pen GLP-1 News
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
June 23, 2026
How To Get $50 GLP-1
<p>Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as <strong>$50 per month</strong> through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.</p><p>We discuss:<br>✅ Medicare Bridge Program eligibility requirements<br>✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates<br>✅ BMI and comorbidity qualifications<br>✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access<br>✅ How Medicare patients can obtain GLP-1 medications<br>✅ Why obesity is finally being treated as a chronic disease<br>✅ The future of obesity medicine and Medicare coverage<br>✅ Concerns about access to care vs access to medication<br>✅ Muscle loss, nutrition, strength training, and healthy weight loss<br>✅ The Treat and Reduce Obesity Act (TROA)</p><p>This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.</p><p>📖 Read more obesity medicine news at <strong>Obesity.News</strong><br>🔗 All links: <strong>linktr.ee/manonthemounjaro</strong></p><p>#GLP1 #Medicare #Zepbound #Wegovy #Obesity #WeightLoss #ObesityMedicine #MedicareBridgeProgram #Tirzepatide #Semaglutide #Foundayo #Orforglipron #Prediabetes #Type2Diabetes #WeightManagement #AngelaFitch #OnThePen #MedicareCoverage #GLP1News #ObesityTreatment #HealthcarePolicy #WeightLossMedication #ChronicDisease #Mounjaro #Retatrutide #Lilly #NovoNordisk #ObesityAdvocacy #GLP1Community #MedicarePatients</p>
June 16, 2026
What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
<p>ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.</p><p><br></p><p>We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!</p><p><br></p><p>From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?</p><p><br></p><p>In this episode:</p><p><br></p><p>✅ Survodutide obesity and liver fat reduction data</p><p>✅ Mazdutide Phase 3 obesity and diabetes results</p><p>✅ UBT251 triple agonist weight loss data</p><p>✅ Berobenatide (MET-097) long-acting GLP-1 updates</p><p>✅ CagriSema diabetes and obesity trial results</p><p>✅ Zenagamtide (Amycretin) injectable and oral development</p><p>✅ Petrelintide amylin agonist info</p><p>✅ Future GLP-1, GIP, glucagon, and amylin therapies</p><p><br></p><p>The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.</p><p><br></p><p>Read more obesity medicine news at obesity.news</p><p><br></p><p>🔗 Linktree: linktr.ee/manonthemounjaro</p><p><br></p><p>#ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen</p>
June 11, 2026
Retatrutide Just Reached Bariatric Surgery Results
<p>Dave sits down with nurse practitioner and former Retatrutide clinical trial participant <strong>David White</strong> to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.</p><p><br></p><p><a href="www.otplinks.com" target="_blank" rel="noopener noreferer">otplinks.com</a></p>
197 total episodes available
Similar Podcasts
Discover related shows you might enjoy
The GLP-1 Podcast Show
Wisenetix
GLP-1 Hub: Support, Community, and Weight Loss
Ana Reisdorf, MS, RD
Drop The Weight with Elizabeth McGann
Elizabeth McGann
Game-Changing Health
Gianna Beasley
The Plus SideZ: Cracking the Obesity Code
Kim Carlos
The Obesity Guide with Matthea Rentea MD
Matthea Rentea MD
Fat Science
Dr Emily Cooper
The Dr. Tyna Show
Dr. Tyna Moore
Docs Who Lift
Docs Who Lift
The Tamsen Show
Tamsen Fadal
The Hunter Williams Podcast
Hunter Williams
The Peptide Podcast
The Peptide Queen
Everyday Wellness
Everyday Wellness™
Peptide of The Week
JD Denham and Will Haas
Deep-dive analytics for On The Pen GLP-1 News
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is On The Pen GLP-1 News?
<p>On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.</p><p><br /></p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.